Phase III trial indicates ultra-low-dose nivolumab may improve survival over chemotherapy in advanced solid tumors
A Tiny Dose of This Cancer Drug Is Outperforming Chemo
This Phase III randomized trial evaluated ultra-low-dose nivolumab against standard chemotherapy in patients with advanced solid tumors prog…
Giving a much smaller dose of a powerful cancer drug can extend life with fewer side effects, making treatment more tolerable and accessible…
Magrolimab plus docetaxel shows limited efficacy in metastatic lung and urothelial cancers
New Drug Combo Fails to Shrink Tough Lung and Bladder Cancers
This cohort study evaluated magrolimab plus docetaxel in patients with metastatic non-small cell lung cancer, small cell lung cancer, and ur…
This study shows that adding a new drug to standard chemotherapy did not help patients with advanced lung or bladder cancer live longer or s…
Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression.
New Pill Slows Advanced Prostate Cancer After Other Drugs Fail
A randomized phase III trial in 417 patients with metastatic castration-resistant prostate cancer after progression on or intolerance to abi…
A new daily pill slowed advanced prostate cancer progression by 42 percent in men whose disease grew despite standard hormone therapy and ch…
Meta-analysis of intravesical gemcitabine/docetaxel versus BCG in non-muscle-invasive bladder cancer
A Two-Drug Bladder Wash May Rival the Gold Standard in Shortage
This systematic review and meta-analysis evaluated intravesical gemcitabine and docetaxel combination therapy versus Bacillus Calmette-Guéri…
A combination bladder rinse may match the standard treatment for early bladder cancer, which matters because BCG has been in short supply fo…
Phase III trial tests TTFields plus standard therapy for stage 4 NSCLC after platinum failure
Can adding electric fields to standard treatment help people with advanced lung cancer?
A prospective, randomized phase III trial in 291 patients with stage 4 NSCLC after platinum progression compared TTFields plus standard ther…
Doctors are testing if adding a wearable electric field device to standard drugs helps people with advanced lung cancer live longer after ch…
Study Validates Genotype Predictor of TIPN in African American Breast Cancer Patients
Could your genes predict nerve pain from breast cancer treatment?
This phase II trial with 249 participants evaluates a germline predictor of taxane-induced peripheral neuropathy (TIPN) in African American …
A genetic marker may predict severe nerve pain from breast cancer chemo in African American patients, with docetaxel possibly causing fewer …